Mutations distal to the substrate site can affect varicella zoster virus thymidine kinase activity: Implications for drug design

Molecular Pharmacology

Volumn 69, Issue 6, 2006, Pages 1891-1896

  Omari, Kamel El ^a   Liekens, Sandra ^b   Bird, Louise E ^a   Balzarini, Jan ^b   Stammers, David K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2' DEOXY BETA DEXTRO RIBOFURANOSYL) 6 OCTYL 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; ACICLOVIR; BENZENE DERIVATIVE; CF 1368; CF 1743; GANCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; BINDING SITES; DIMERIZATION; DRUG DESIGN; ENZYME INHIBITORS; HERPESVIRUS 3, HUMAN; HETEROCYCLIC COMPOUNDS, 2-RING; INHIBITORY CONCENTRATION 50; MUTAGENESIS, SITE-DIRECTED; MUTATION; NUCLEOSIDES; PRODRUGS; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; THYMIDINE KINASE; VIRAL PROTEINS;

EID: 33745121906     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.023002     Document Type: Article

References (22)

1. Amrhein I, Wurth C, Bohner T, Hofbauer R, Folkers G, and Scapozza L (2000) Highly purified recombinant varicella Zoster virus thymidine kinase is a homodimer. Protein Expr Purif 18:338-345.
2. Andrei G, Snoeck R, Neyts J, Sandvold ML, Myhren F, and De Clercq E (2000) Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. Antiviral Res 45:157-167.
3. Ashida N, Watanabe Y, Miura S, Kano F, Sakata S, Yamaguchi T, Suzutani T, and Machida H (1997) Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus. Antiviral Res 35:167-175.
4. Balzarini J and McGuigan C (2002a) Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication. J Antimicrob Chemother 50:5-9.
5. Balzarini J and McGuigan C (2002b) Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 1587:287-295.
6. Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, and McGuigan C (2002) Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 61:1140-1145.
7. Bird LE, Ren J, Wright A, Leslie KD, Degreve B, Balzarini J, and Stammers DK (2003) Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem 278:24680-24687.
8. Cohen JI, Brunell PA, Straus SE, and Krause PR (1999) Recent advances in varicella-zoster virus infection. Ann Intern Med 130:922-932.
9. De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 68:2301-2315.
10. Degreve B, Andrei G, Izquierdo M, Piette J, Morin K, Knaus EE, Wiebe LI, Basrah I, Walker RT, De Clercq E, et al. (1997) Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther 4:1107-1114.
11. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, and Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2- hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716-5720.
12. Grignet-Debrus C and Calberg-Bacq CM (1997) Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther 4:560-569.
13. Kussmann-Gerber S, Kuonen O, Folkers G, Pilger BD, and Scapozza L (1998) Drug resistance of herpes simplex virus type 1-structural considerations at the molecular level of the thymidine kinase. Eur J Biochem 255:472-481.
14. McGuigan C, Barucki H, Carangio A, Blewett S, Andrei G, Snoeck R, De Clercq E, Balzarini J, and Erichsen JT (2000) Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 43:4993-4997.
15. McGuigan C, Yarnold CJ, Jones G, Velazquez S, Barucki H, Brancale A, Andrei G, Snoeck R, De Clercq E, and Balzarini J (1999) Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 42:4479-4484.
16. Naesens L and De Clercq E (2001) Recent developments in herpesvirus therapy. Herpes 8:12-16.
17. Pedelini L, Garcia-Gimeno MA, Marina A, Gomez-Zumaquero JM, Rodriguez-Bada P, Lopez-Enriquez S, Soriguer FC, Cuesta-Munoz AL, and Sanz P (2005) Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations. Protein Sci 14:2080-2086.
18. Ren J, Esnouf RM, Hopkins AL, Jones EY, Kirby I, Keeling J, Ross CK, Larder BA, Stuart DI, and Stammers DK (1998) 3′-Azido-3′- deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci USA 95:9518-9523.
19. Roberts GB, Fyfe JA, Gaillard RK, and Short SA (1991) Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol 65:6407-6413.
20. Sienaert R, Naesens L, Brancale A, De Clercq E, McGuigan C, and Balzarini J (2002) Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 61:249-254.
21. Stevens JG (1989) Human herpesviruses: a consideration of the latent state. Microbiol Rev 53:318-332.
22. Suzutani T, Davies LC, and Honess RW (1993) Kinetic studies of the predicted substrate-binding site of varicella-zoster virus thymidine kinase. J Gen Virol 74:1011-1016.